文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

赞比亚和南非艾滋病毒阳性与艾滋病毒阴性人群健康相关生活质量的差异:HPTN 071(PopART)试验的横断面基线调查。

Differences in health-related quality of life between HIV-positive and HIV-negative people in Zambia and South Africa: a cross-sectional baseline survey of the HPTN 071 (PopART) trial.

机构信息

Department of Infectious Disease Epidemiology, Imperial College London, London, UK.

Department of Economics, Stellenbosch University, Stellenbosch, South Africa.

出版信息

Lancet Glob Health. 2017 Nov;5(11):e1133-e1141. doi: 10.1016/S2214-109X(17)30367-4. Epub 2017 Sep 27.


DOI:10.1016/S2214-109X(17)30367-4
PMID:28964756
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5640509/
Abstract

BACKGROUND: The life expectancy of HIV-positive individuals receiving antiretroviral therapy (ART) is approaching that of HIV-negative people. However, little is known about how these populations compare in terms of health-related quality of life (HRQoL). We aimed to compare HRQoL between HIV-positive and HIV-negative people in Zambia and South Africa. METHODS: As part of the HPTN 071 (PopART) study, data from adults aged 18-44 years were gathered between Nov 28, 2013, and March 31, 2015, in large cross-sectional surveys of random samples of the general population in 21 communities in Zambia and South Africa. HRQoL data were collected with a standardised generic measure of health across five domains. We used β-distributed multivariable models to analyse differences in HRQoL scores between HIV-negative and HIV-positive individuals who were unaware of their status; aware, but not in HIV care; in HIV care, but who had not initiated ART; on ART for less than 5 years; and on ART for 5 years or more. We included controls for sociodemographic variables, herpes simplex virus type-2 status, and recreational drug use. FINDINGS: We obtained data for 19 750 respondents in Zambia and 18 941 respondents in South Africa. Laboratory-confirmed HIV status was available for 19 330 respondents in Zambia and 18 004 respondents in South Africa; 4128 (21%) of these 19 330 respondents in Zambia and 4012 (22%) of 18 004 respondents in South Africa had laboratory-confirmed HIV. We obtained complete HRQoL information for 19 637 respondents in Zambia and 18 429 respondents in South Africa. HRQoL scores did not differ significantly between individuals who had initiated ART more than 5 years previously and HIV-negative individuals, neither in Zambia (change in mean score -0·002, 95% CI -0·01 to 0·001; p=0·219) nor in South Africa (0·000, -0·002 to 0·003; p=0·939). However, scores did differ between HIV-positive individuals who had initiated ART less than 5 years previously and HIV-negative individuals in Zambia (-0·006, 95% CI -0·008 to -0·003; p<0·0001). A large proportion of people with clinically confirmed HIV were unaware of being HIV-positive (1768 [43%] of 4128 people in Zambia and 2026 [50%] of 4012 people in South Africa) and reported good HRQoL, with no significant differences from that of HIV-negative people (change in mean HRQoL score -0·001, 95% CI -0·003 to 0·001, p=0·216; and 0·001, -0·001 to 0·001, p=0·997, respectively). In South Africa, HRQoL scores were lower in HIV-positive individuals who were aware of their status but not enrolled in HIV care (change in mean HRQoL -0·004, 95% CI -0·01 to -0·001; p=0·010) and those in HIV care but not on ART (-0·008, -0·01 to -0·004; p=0·001) than in HIV-negative people, but the magnitudes of difference were small. INTERPRETATION: ART is successful in helping to reduce inequalities in HRQoL between HIV-positive and HIV-negative individuals in this general population sample. These findings highlight the importance of improving awareness of HIV status and expanding ART to prevent losses in HRQoL that occur with untreated HIV progression. The gains in HRQoL after individuals initiate ART could be substantial when scaled up to the population level. FUNDING: National Institute of Allergy and Infectious Diseases, National Institute on Drug Abuse, National Institute of Mental Health, President's Emergency Plan for AIDS Relief, International Initiative for Impact Evaluation, the Bill & Melinda Gates Foundation.

摘要

背景:接受抗逆转录病毒疗法(ART)的 HIV 阳性个体的预期寿命接近 HIV 阴性个体。然而,对于这些人群在健康相关生活质量(HRQoL)方面的比较,人们知之甚少。我们旨在比较赞比亚和南非的 HIV 阳性和 HIV 阴性人群的 HRQoL。

方法:作为 HPTN 071(PopART)研究的一部分,于 2013 年 11 月 28 日至 2015 年 3 月 31 日,在赞比亚和南非 21 个社区的随机样本的大型横断面调查中收集了年龄在 18-44 岁的成年人的数据。使用跨越五个领域的标准通用健康衡量标准来收集 HRQoL 数据。我们使用β分布多变量模型分析了未意识到自身状况的 HIV 阴性和 HIV 阳性个体、已意识到但未接受 HIV 护理、已接受 HIV 护理但未开始接受 ART、接受 ART 少于 5 年和接受 ART 5 年或以上者的 HRQoL 评分之间的差异。我们包括了社会人口统计学变量、单纯疱疹病毒 2 型状况和娱乐性药物使用的对照。

结果:我们获得了来自赞比亚的 19330 名受访者和来自南非的 18004 名受访者的数据。在赞比亚的 19330 名受访者和南非的 18004 名受访者中,有实验室确诊的 HIV 状态,其中 4128 名(21%)来自赞比亚的 19330 名受访者和 4012 名(22%)来自南非的 18004 名受访者有实验室确诊的 HIV。我们获得了来自赞比亚的 19637 名受访者和来自南非的 18429 名受访者的完整 HRQoL 信息。在赞比亚(平均评分变化-0·002,95%CI-0·01 至 0·001;p=0·219)和南非(0·000,-0·002 至 0·003;p=0·939),启动 ART 时间超过 5 年的个体与 HIV 阴性个体之间的 HRQoL 评分没有显著差异。然而,在赞比亚,启动 ART 时间少于 5 年的 HIV 阳性个体与 HIV 阴性个体之间的评分确实存在差异(-0·006,95%CI-0·008 至 -0·003;p<0·0001)。相当一部分有临床确诊 HIV 的人不知道自己感染了 HIV(4128 人中的 1768 人[43%]在赞比亚和 4012 人中的 2026 人[50%]在南非),并报告了良好的 HRQoL,与 HIV 阴性个体没有显著差异(平均 HRQoL 评分变化-0·001,95%CI-0·003 至 0·001,p=0·216;0·001,-0·001 至 0·001,p=0·997)。在南非,已意识到自身状况但未参加 HIV 护理的 HIV 阳性个体(平均 HRQoL 评分变化-0·004,95%CI-0·01 至 -0·001;p=0·010)和接受 HIV 护理但未接受 ART 的个体(-0·008,-0·01 至 -0·004;p=0·001)的 HRQoL 评分低于 HIV 阴性个体,但差异幅度较小。

解释:ART 成功地帮助减少了这一一般人群样本中 HIV 阳性和 HIV 阴性个体之间在 HRQoL 方面的不平等。这些发现强调了提高 HIV 感染状况的认识和扩大 ART 的重要性,以防止未经治疗的 HIV 进展所导致的 HRQoL 丧失。当在人群层面上扩大规模时,个体开始接受 ART 后获得的 HRQoL 增益可能会很大。

资金:国家过敏和传染病研究所、国家药物滥用研究所、国家心理健康研究所、总统艾滋病救援计划、影响评估国际倡议、比尔和梅琳达盖茨基金会。

相似文献

[1]
Differences in health-related quality of life between HIV-positive and HIV-negative people in Zambia and South Africa: a cross-sectional baseline survey of the HPTN 071 (PopART) trial.

Lancet Glob Health. 2017-9-27

[2]
Cost and cost-effectiveness of a universal HIV testing and treatment intervention in Zambia and South Africa: evidence and projections from the HPTN 071 (PopART) trial.

Lancet Glob Health. 2021-5

[3]
Viral suppression and self-reported ART adherence after 3 years of universal testing and treatment in the HPTN 071 (PopART) community-randomised trial in Zambia and South Africa: a cross-sectional analysis.

Lancet HIV. 2022-11

[4]
HIV testing and treatment coverage achieved after 4 years across 14 urban and peri-urban communities in Zambia and South Africa: An analysis of findings from the HPTN 071 (PopART) trial.

PLoS Med. 2020-4-2

[5]
Impact of universal testing and treatment on sexual risk behaviour and herpes simplex virus type 2: a prespecified secondary outcomes analysis of the HPTN 071 (PopART) community-randomised trial.

Lancet HIV. 2022-11

[6]
Projected outcomes of universal testing and treatment in a generalised HIV epidemic in Zambia and South Africa (the HPTN 071 [PopART] trial): a modelling study.

Lancet HIV. 2022-11

[7]
Tuberculosis prevalence after 4 years of population-wide systematic TB symptom screening and universal testing and treatment for HIV in the HPTN 071 (PopART) community-randomised trial in Zambia and South Africa: A cross-sectional survey (TREATS).

PLoS Med. 2023-9

[8]
Community based distribution of oral HIV self-testing kits in Zambia: a cluster-randomised trial nested in four HPTN 071 (PopART) intervention communities.

Lancet HIV. 2018-12-21

[9]
Demographics of sources of HIV-1 transmission in Zambia: a molecular epidemiology analysis in the HPTN 071 PopART study.

Lancet Microbe. 2024-1

[10]
A universal testing and treatment intervention to improve HIV control: One-year results from intervention communities in Zambia in the HPTN 071 (PopART) cluster-randomised trial.

PLoS Med. 2017-5-2

引用本文的文献

[1]
Quality of life in patients with HBV infection: A systematic review and meta-analysis.

JHEP Rep. 2025-1-8

[2]
Quality of Life Gain Following Treatment Among Breast Cancer Survivors With and Without HIV.

JCO Glob Oncol. 2024-8

[3]
Associations between HIV stigma and health-related quality-of-life among people living with HIV: cross-sectional analysis of data from HPTN 071 (PopART).

Sci Rep. 2024-6-4

[4]
HIV, multimorbidity, and health-related quality of life in rural KwaZulu-Natal, South Africa: A population-based study.

PLoS One. 2024

[5]
Factors associated with fertility intentions among women living with and without human immunodeficiency virus in Zambia.

Womens Health (Lond). 2023

[6]
Factors affecting quality of life in adults with HIV: A local cross-sectional study.

S Afr J Physiother. 2023-11-27

[7]
Evaluation of the health-related quality of life and associated factors in Zimbabwean adults living with HIV: a cross-sectional study.

BMC Res Notes. 2023-10-4

[8]
Health disparities affecting persons living with HIV and using substances in China.

Appl Nurs Res. 2023-10

[9]
Quality of Life in HIV-Positive People in Poland Treated in the City of Bialystok: A Cross-Sectional Study.

J Clin Med. 2023-8-27

[10]
Determinants of health-related quality of life in people with Human Immunodeficiency Virus, failing first-line treatment in Africa.

Health Qual Life Outcomes. 2023-8-21

本文引用的文献

[1]
Determinants of time from HIV infection to linkage-to-care in rural KwaZulu-Natal, South Africa.

AIDS. 2017-4-24

[2]
Health-related quality-of-life of people with HIV in the era of combination antiretroviral treatment: a cross-sectional comparison with the general population.

Lancet HIV. 2014-9-22

[3]
Cost-effectiveness of population-level expansion of highly active antiretroviral treatment for HIV in British Columbia, Canada: a modelling study.

Lancet HIV. 2015-9

[4]
Making the economic case for universal ART access.

Lancet HIV. 2015-9

[5]
Trends in CD4 count at presentation to care and treatment initiation in sub-Saharan Africa, 2002-2013: a meta-analysis.

Clin Infect Dis. 2015-4-1

[6]
Excess burden of depression among HIV-infected persons receiving medical care in the united states: data from the medical monitoring project and the behavioral risk factor surveillance system.

PLoS One. 2014-3-24

[7]
HPTN 071 (PopART): rationale and design of a cluster-randomised trial of the population impact of an HIV combination prevention intervention including universal testing and treatment - a study protocol for a cluster randomised trial.

Trials. 2014-2-13

[8]
Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada.

PLoS One. 2013-12-18

[9]
Cost-effectiveness of HIV treatment as prevention in serodiscordant couples.

N Engl J Med. 2013-10-31

[10]
Elimination of HIV in South Africa through expanded access to antiretroviral therapy: a model comparison study.

PLoS Med. 2013-10-22

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索